Access to reliable GMP peptide APIs gives compounders the flexibility to work with a wider range of active ingredients without having to build their entire proposition around a single therapeutic category. It creates the foundations for a more responsive formulation model — one capable of adapting as prescribing patterns, patient requirements and peptide science evolve.

And in Germany, where personalised medicine already has a strong foothold, the opportunity is particularly compelling.

The peptide market is getting bigger — and broader

The most visible growth story around peptides today is undoubtedly metabolic health.

Germany’s pharmaceutical market generated €67.9 billion in revenue in 2025, with sales increasing by 5.9% year on year. Germany also remains Europe’s largest pharmaceutical market and one of the world’s major centres for pharmaceutical R&D.

Within that wider market, GLP-1 therapies have become a major force. Novo Nordisk launched the oral version of Wegovy in Germany in September 2026, adding another formulation to an already rapidly developing obesity-treatment market. Globally, the obesity-treatment market is now expected to exceed $100 billion annually by 2030.

But focusing exclusively on GLP-1s risks missing the bigger picture.

Peptide development is expanding across multiple therapeutic areas, while the underlying manufacturing technology is becoming increasingly sophisticated. The European Medicines Agency’s updated 2026 guideline on the development and manufacture of synthetic peptides specifically addresses areas including manufacturing processes, characterisation, specifications, analytical controls, impurities, stereoisomers and truncated or deletion sequences.

That is significant for compound pharmacies.

It demonstrates that peptide APIs are becoming a more technically defined and closely scrutinised category — and that compounders considering them need to think beyond simply sourcing an active ingredient.

A portfolio approach makes more sense than chasing one peptide

The commercial opportunity for a German compound pharmacy is not necessarily to predict which individual peptide will become the next major product.

It is to develop the capability to respond when demand appears.

That distinction matters.

A compound pharmacy that establishes a dependable supply route for GMP peptide APIs can potentially support multiple formulations and therapeutic applications from the same underlying procurement infrastructure. Instead of repeatedly searching for suppliers when a new formulation requirement emerges, it can develop a more structured peptide sourcing strategy.

That makes the portfolio more scalable.

It can also make procurement more efficient. Supplier relationships, quality documentation, specifications and internal processes can be developed around a consistent standard rather than reinvented for every new API.

For businesses operating in an increasingly competitive German pharmacy market, that flexibility has real value.

ABDA reported that Germany had 16,601 operating pharmacies at the end of 2025 — 440 fewer than a year earlier and the lowest number in almost five decades. Since 2013, the total number has fallen by almost 20%.

In a market where the number of operating sites is shrinking, differentiation becomes increasingly important.

Specialist compounding is one way to create it.

Personalisation is becoming a much larger pharmaceutical conversation

Peptides fit naturally into the broader move towards personalised medicine.

Germany’s personalised medicine market was valued at approximately $32.4 billion in 2024 and is forecast to reach more than $72 billion by 2033, representing projected annual growth of 9.4% between 2025 and 2033.

While personalised medicine encompasses far more than compounding or peptide therapy, the direction of travel is clear: treatment is increasingly moving away from a onesize-fits-all model.

That creates a stronger rationale for flexible formulation capabilities.

For compound pharmacies, the advantage is the ability to respond to specific prescribing requirements rather than relying exclusively on commercially manufactured presentations. Where an appropriate prescription and legitimate compounding pathway exist, access to suitable APIs can allow formulations to be developed around the needs of the individual patient.

Peptides can therefore become part of a wider formulation strategy rather than a standalone product experiment.

GMP gives the portfolio a stronger foundation

A growing portfolio is only useful if the underlying ingredients are dependable.

This is where GMP sourcing becomes particularly important.

The EMA’s 2026 chemistry guidance for active substances has expanded its focus on areas including starting materials, recovery and reprocessing, while adding further recommendations concerning impurities such as N-nitrosamines.

For peptide APIs, the importance of analytical control is even more apparent. The specific characteristics of peptide synthesis mean that the quality of an API cannot simply be assumed from its chemical name. Purity, identity, related substances and potential sequence variants all matter.

For a compound pharmacy building a peptide portfolio, this makes supplier selection part of the formulation strategy.

A GMP-grade API provides a much stronger starting point for internal quality procedures, incoming-material checks and batch documentation. It also gives compounders greater confidence that the material originates from a controlled manufacturing environment.

That is particularly valuable when expanding into APIs that the team may not have handled previously.

The real advantage is flexibility

The strongest peptide portfolio is not necessarily the largest.

It is the one that can evolve.

A compound pharmacy may initially have demand for one peptide API and later encounter

interest in a completely different therapeutic application. Having an established relationship with a specialist API supplier makes that transition significantly easier.

Instead of treating each new ingredient as a standalone sourcing project, the pharmacy can work with a supplier that understands its requirements and can identify suitable GMP manufacturing sources.

This is where specialist distribution adds value beyond simply moving material from A to B.

MedicaPharma works with an international network of more than 400 GMP manufacturers, providing access to specialist APIs and supporting pharmaceutical customers with sourcing, documentation and GDP-compliant distribution. That infrastructure is particularly relevant for compound pharmacies looking to build a broader portfolio without taking on unnecessary supply-chain complexity.

The result is a more agile model: identify the formulation opportunity, establish the API requirement, verify the quality documentation and develop the preparation within the compound pharmacy’s own professional and regulatory framework.

Demand is changing — compounders need to be ready

Recent developments around GLP-1 medicines demonstrate just how quickly pharmaceutical demand can shift.

Germany has now entered another phase of the obesity-treatment market with the launch of oral Wegovy, while research continues to examine dosing, tolerability and longer-term use of GLP-1 therapies. A recent study reported that even starter doses of semaglutide and tirzepatide produced measurable weight loss, although substantially greater reductions were seen at higher doses.

At the same time, German pharmacists are seeing the practical consequences of increasingly complex therapies. ABDA’s Arzneimittelkommission recorded 11,154 spontaneous reports of suspected quality defects and adverse effects in 2025, with 535 reports specifically concerning potential application errors involving the Mounjaro KwikPen.

The message for compound pharmacies is not that peptides are easy.

It is that expertise matters.

As peptide-based therapies become more prominent, compounders with strong formulation processes and reliable access to quality APIs will be better placed to assess legitimate opportunities as they emerge.

Build the capability before the next opportunity arrives

The peptide market is developing too quickly for compound pharmacies to take a wait-andsee approach.

The next opportunity may come from metabolic medicine. It may come from hormonerelated treatment, a specialist indication or an emerging formulation requirement. What these opportunities have in common is the need for dependable API sourcing and the ability to move from demand to formulation without compromising quality.

For German compound pharmacies, building that capability now can provide a meaningful competitive advantage.

GMP peptide APIs are not simply ingredients to add to a catalogue. They are the building blocks of a flexible, specialist formulation portfolio — one capable of evolving alongside pharmaceutical innovation and changing patient requirements.

MedicaPharma can help German compound pharmacies source GMP peptide APIs from qualified manufacturing partners, with specialist sourcing support and the documentation required to support a robust pharmaceutical supply chain.

If your compound pharmacy is looking to expand its peptide portfolio or source a specific GMP peptide API, contact MedicaPharma today to discuss your requirements and request a quotation.